STONY BROOK, N.Y. February 13, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today reported financial results for its first quarter of fiscal 2025 ended December 31, 2024. The Company’s Form 10-Q, once filed, can be viewed on the [...]
STONY BROOK, N.Y. February 12, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders [...]
STONY BROOK, N.Y. – February 11, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the “Special Meeting”) to be held on Friday, February 14, [...]
STONY BROOK, N.Y. January 8, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results. [...]
STONY BROOK, N.Y. – December 17, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. An update on the buildout of the Company’s GMP manufacturing facility [...]
STONY BROOK, N.Y. – December 16, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024. The Company will [...]
STONY BROOK, N.Y., October 15, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit. Maxim Group LLC is presenting the virtual summit [...]
STONY BROOK, N.Y., January 31, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities purchase agreements (SPAs) with certain existing institutional investors (collectively the “Holders”) for the issuance and sale of an aggregate of 5,644,061 of its shares of common [...]
The Specimen Accessioner works closely with Applied DNA Clinical Labs personnel to catalog patient specimens, such as: swab, transport media, body fluids (blood, urine, etc.) or tissue samples, for review. Those samples are processed and examined by laboratory professionals, doctors, and nurses for diagnosis and treatment. Job Duties and Responsibilities Verifies all specimens that [...]